Products Erenumab was approved in many countries, in the EU, and in the United States in 2018 as a solution for injection in a prefilled pen and a prefilled syringe (Aimovig, Novartis / Amgen). Structure and properties Erenumab is a human IgG2 monoclonal antibody directed against the CGRP receptor. It has a molecular weight of … Erenumab
Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Rituximab is commercially available as a concentrate for the preparation of an infusion solution and as a solution for subcutaneous injection (MabThera, MabThera subcutaneous). It has been approved in many countries and in the United States since 1997 and in the EU since 1998. Biosimilars are available in some countries, including many (2018, Rixathon, … Rituximab
Products Infusion is the administration of a larger volume of fluid, usually intravenously into the blood, but also directly into organs or tissues. This is in contrast to injections, in which only small volumes are injected. The pharmacopoeia places special requirements on infusion preparations and the corresponding containers. Among other things, they must be germ-free, … Infusions
Products Obiltoxaximab was approved in the United States in 2016 as an infusion product (Anthim). It has not yet been registered in many countries. Obiltoxaximab was developed with funding from national organizations and is intended primarily for the treatment of victims of a terrorist attack with anthrax spores (Strategic National Stockpile). Structure and properties Obiltoxaximab … Obiltoxaximab
Symptoms Rheumatoid arthritis is a chronic, inflammatory and systemic joint disease. It manifests as pain, symmetrically tense, achy, warm, and swollen joints, swelling, and morning stiffness that lasts for more than an hour. Initially, the hands, wrists, and feet are most affected, but later numerous other joints are also affected. Over time, deformities and rheumatoid … Rheumatoid Arthritis Causes and Treatment
Symptoms Symptoms of Covid-19 include (selection): Fever Cough (irritating cough or with sputum) Respiratory disorders, shortness of breath, shortness of breath. Feeling sick, fatigue Cold symptoms: runny nose, stuffy nose, sore throat. Pain in the limbs, muscle and joint pain. Gastrointestinal complaints: Diarrhea, nausea, vomiting, abdominal pain. Nervous system: impairment of the sense of smell … COVID-19
Products TNF-α inhibitors are commercially available as injectable and infusion preparations. Infliximab (Remicade) was the first agent from this group to be approved in 1998, and in many countries in 1999. Biosimilars of some representatives are now available. Others will follow in the next few years. This article refers to biologics. Small molecules can also … TNF-Α Inhibitors
Symptoms Possible symptoms of multiple sclerosis include: Weakness, numbness of the extremities. Visual disturbances, eye pain, optic neuritis. Paresthesias (eg, formication, tingling), pain, nerve pain. Tremor, coordination / balance disorders. Speech and swallowing disorders Dizziness, lightheadedness Fatigue Urinary incontinence, constipation Sexual function disorders, erectile dysfunction The disease is often relapsing and recurrent (relapsing-remitting multiple sclerosis), … Multiple Sclerosis Causes and Treatment
Most common mechanism of action Most drugs bind to a macromolecular target structure called a drug target. These are usually proteins such as receptors, transporters, channels, and enzymes, or nucleic acids. For example, opioids interact with endogenous opioid receptors to relieve pain. Targets can also be exogenous structures. Penicillins inhibit bacterial enzymes responsible for building … Mechanism of Action
Products Trastuzumab is commercially available as a lyophilizate for preparation of an infusion concentrate (Herceptin, biosimilars). It has been approved in many countries since 1999 (US: 1998, EU: 2000). In 2016, an additional solution for subcutaneous injection for breast cancer therapy was released in many countries (Herceptin subcutaneous). It was available earlier in other countries. … Trastuzumab
Products Alemtuzumab is commercially available as a concentrate for the preparation of an infusion solution (Lemtrada). It was approved in 2014. Alemtuzumab was originally approved for leukemia treatment and marketed as MabCampath (approved in 2001). Structure and properties Alemtuzumab is a humanized IgG1 kappa monoclonal antibody to CD52 produced by biotechnological methods. It has a … Alemtuzumab
